General Request for Proposals – The Alzheimer’s Drug Discovery Foundation (ADDF)

Objecte

The Alzheimer's Drug Discovery Foundation supports promising, diverse international research projects to develop new drugs for Alzheimer's and related dementias, including vascular, Lewy body, and frontotemporal dementias.
ADDF's goal is to fill the critical translational funding gap that exists between basic research and later-stage drug development. ADDF funds three categories of research:

  • Drug discovery and preclinical development, including high throughput screening, medicinal chemistry, lead optimization, in vivo efficacy, safety and toxicology, formulation of the drug, and scale-up
  • Clinical trials
  • Early detection, such as biomarkers and neuroimaging
Altres

DOTACIÓ

  • Drug discovery: $150,000 – $600,000
  • Program to accelerate clinical trials : up to $3 million
  • Biomarkers development: $150,000 – $300,000
  • Prevention beyond the pipeline: $50,000-$100,000 (epidemiological analyses), up to $3 million

DURADA

  • Drug discovery: 1 year, potential for follow-up funding
  • Program to accelerate clinical trials : multi-year
  • Biomarkers development: 1-2 years, potential for follow-up funding
  • Prevention beyond the pipeline: 1 year (epidemiological analyses), multi-year (clinical trials)

 

AVÍS IMPORTANT 
Deadlines for 2018 RFPs: 
LETTERS OF INTENT:

  • January 19,
  • April 13
  • July 13
  • October 12
    INVITED FULL PROPOSALS:
  • February 9
  • May 11
  • August 10
  • November 9

Estàs interessat?

Omple el següent formulari per rebre més informació: